Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
26 janv. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline to participate at Conferences during January 2021
04 janv. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
14 déc. 2020 07h00 HE
|
Freeline Therapeutics
Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with...
Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference
19 nov. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline appoints Mark Baldry as Chief Commercial Officer
02 nov. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit
30 oct. 2020 07h00 HE
|
Freeline Therapeutics
- Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes - Potentially increasing safety and efficacy in Freeline’s AAV delivery...
Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights
29 oct. 2020 16h15 HE
|
Freeline Therapeutics
Will report updated durability data from Phase 1/2 B-AMAZE trial in Haemophilia B in Q4 Third wholly-owned programme expected to be in the clinic in 2021 Strong cash position with over $250 million...
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference at the revised time of 3.45 pm EDT on 6 October
29 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scientific Officer
28 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based...
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference
25 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...